1. SEER stat fact sheets: myeloma. National Institutes of Health, NationalCancer Institute Surveillance, Epidemiology, and End Results Program. http://seer.cancer.gov/statfacts/html/mulmy.html. Accessed 23 Dec 2019.
2. Kazandijan D. Multiple myeloma epidemiology and survival, a unique malignancy. Semin Oncol. 2016;43(6):676–81.
3. Shortt CP, Gleeson TG, Breen KA, McHugh J, O’Connell MJ, O’Gorman PJ, et al. Whole-body MRI versus PET in assessment of multiple myeloma disease activity. AJR Am J Roentgenol. 2009;192(4):980.
4. Mhaskar R, Kumar A, Miladinovic B, Djulbegovic B. Bisphosphonates in multiple myeloma: an updated network meta-analysis. Cochrane Database Syst Rev. 2017;12:CD003188.
5. Mhaskar R, Redzepovic J, Wheatley K, Clark OA, Miladinovic B, Glasmacher A, et al. Bisphosphonates in multiple myeloma: a network meta-analysis. Cochrane Database Syst Rev. 2012;16(5):CD003188.